Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?

Autor: Dupont M; Department of Medical Oncology, Godinot Cancer Institute, 1 Rue du Général Koenig, 51100, Reims, France., Carlier C; Department of Medical Oncology, Godinot Cancer Institute, 1 Rue du Général Koenig, 51100, Reims, France. claire.carlier@chu-reims.fr.; Department of Gastroenterology and Digestive Oncology, CHU Reims, University of Reims Champagne-Ardenne, Reims, France. claire.carlier@chu-reims.fr., Gower-Rousseau C; Department of Research and Public Health, CHU Reims, Reims, France., Barbier-Lider P; Department of Pharmacy, Nancy University Hospital, Vandoeuvre-lès-Nancy, France., Botsen D; Department of Medical Oncology, Godinot Cancer Institute, 1 Rue du Général Koenig, 51100, Reims, France.; Department of Gastroenterology and Digestive Oncology, CHU Reims, University of Reims Champagne-Ardenne, Reims, France., Brasseur M; Department of Gastroenterology and Digestive Oncology, CHU Reims, University of Reims Champagne-Ardenne, Reims, France., Burgevin A; Department of Gastroenterology and Digestive Oncology, Nancy University Hospital, Lorraine University, Vandoeuvre-lès-Nancy, France., Chourbagi C; Department of Pharmacy, Amiens University Hospital, Amiens, France., D'Almeida R; Department of Gastroenterology and Digestive Oncology, CHU Reims, University of Reims Champagne-Ardenne, Reims, France., Hautefeuille V; Department of Gastroenterology and Digestive Oncology, Amiens University Hospital, University of Picardie Jules Verne, Amiens, France., Hentzien M; Department of Infectious Diseases and Internal Medicine, CHU Reims, University of Reims Champagne-Ardenne, Reims, France., Lambert A; Department of Medical Oncology, Lorraine Cancer Institute, Vandoeuvre-lès-Nancy, France., Lamuraglia M; Department of Medical Oncology, Amiens University Hospital, University of Picardie Jules-Vernes, Amiens, France., Lavau-Denes S; Department of Medical Oncology, Limoges University Hospital, Limoges, France., Lopez A; Department of Gastroenterology and Digestive Oncology, Nancy University Hospital, Lorraine University, Vandoeuvre-lès-Nancy, France., Parent D; Department of Pharmacy, Godinot Cancer Institute, Reims, France., Slimano F; Department of Pharmacy, CHU Reims, University of Reims Champagne-Ardenne, Reims, France., Brugel M; Department of Gastroenterology and Digestive Oncology, CHU Reims, University of Reims Champagne-Ardenne, Reims, France., Bouché O; Department of Gastroenterology and Digestive Oncology, CHU Reims, University of Reims Champagne-Ardenne, Reims, France.
Jazyk: angličtina
Zdroj: BMC cancer [BMC Cancer] 2022 Nov 25; Vol. 22 (1), pp. 1219. Date of Electronic Publication: 2022 Nov 25.
DOI: 10.1186/s12885-022-10192-4
Abstrakt: Background: Previous studies have observed an increased incidence of Cetuximab-induced hypersensitivity infusion reactions (CI-IRs) in the southeastern states of the USA. Tick's bites were suspected of generating cross-reactions between cetuximab and alpha-gal. This study aims was to describe the incidence and associated risk factors of CI-IRs, in the French areas chosen according to their Lyme disease incidence.
Patients and Methods: A retrospective chart review was conducted on patients that received cetuximab infusion from January 2010 to June 2019 in 4 French areas with different Lyme disease incidence rates.
Results: Of 1392 patients, 117 (8.4%) experienced a CI-IR, including 68 severe (grade 3 or 4) reactions (4.9%). This CI-IR incidence was significantly higher in the Lyme disease high-risk area than in the other areas (13.2% versus 7.1%, 8.1% and 6.4%; P = 0.016). Sex (P = 0.53), premedication (P = 0.91), primary cancer location (P = 0.46) and chemotherapy regimen type (P = 0.78) had no impact on CI-IR incidence in the overall population. In the head and neck squamous cell carcinoma (HNSCC) patient subgroup, CI-IRs were significantly more frequent in the high-risk area (16.4% versus 6.7%, 7.1% and 7.0%; P = 0.0015).
Conclusion: This study suggests that patients treated in the French area with the highest incidence of Lyme disease are at a higher risk of CI-IRs.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje